CC
ALLO icon

Callan Capital’s Allogene Therapeutics ALLO Stock Holding History

Callan Capital’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$30.8K Hold
21,089
– – ﹤0.01% 365
2024
Q4 		$44.9K Hold
21,089
– – ﹤0.01% 340
2024
Q3 		$59K Hold
21,089
– – ﹤0.01% 346
2024
Q2 		$49.1K Hold
21,089
– – ﹤0.01% 312
2024
Q1 		$94.3K Hold
21,089
– – 0.01% 290
2023
Q4 		$67.7K Buy
21,089
+1,865
+10% +$5.29K 0.01% 229
2023
Q3 		$60.9K Hold
19,224
– – 0.01% 198
2023
Q2 		$95.5K Hold
19,224
– – 0.01% 178
2023
Q1 		$95K Hold
19,224
– – 0.01% 178
2022
Q4 		$121K Buy
+19,224
New +$178K 0.01% 179

Other funds holding ALLO

P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Callan Capital's ALLO Position: Q1 2025 in Review

Callan Capital held its Allogene Therapeutics (ALLO) position steady in Q1 2025 at 21,089 shares worth $30.8K. The position accounts for ﹤0.01% of the portfolio, ranked #365.

Callan Capital first reported a position in ALLO in Q4 2022 and has held it in 10 quarters since. The position peaked at $121K in Q4 2022. 171 funds tracked by Wall St. Rank hold ALLO as of Q1 2025.

  • Callan Capital held 21,089 shares of Allogene Therapeutics worth $30.8K as of Q1 2025.
  • Callan Capital left its Allogene Therapeutics share count unchanged in Q1 2025.
  • Allogene Therapeutics made up ﹤0.01% of Callan Capital's portfolio in Q1 2025, its #365 holding.
  • Callan Capital first reported a position in Allogene Therapeutics in Q4 2022 and has held it in 10 quarters since.
  • Callan Capital's Allogene Therapeutics position peaked at $121K in Q4 2022.
  • 171 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2025.

Based on Callan Capital's 13F filing for Q1 2025, filed 29 Apr 2025.